Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Metastatic seeding in clinically undetectable primary CRC

Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA, talks on metastatic seeding in clinically undetectable primary colorectal cancer (CRC). Prof. Lenz discusses the possibility of using next-generation sequencing (NGS) to test primary tumors and predict if they are metastatic, rather than the current approach of using liquid biopsies to detect minimal residual disease (MRD). The potential to be able to identify a molecular signature present in the primary tumor at the time of diagnosis and know if a tumor is metastatic or not and the implications of this are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Disclosures

Ad Boards/Lectures: BMS, Roche, Oncocyte, Fulgent, Bayer, G1 Therapeutics, Jazz Therapeutics, Abbvie, Merck, Merck KG, Isofol

Clinical Trial Support: NCI, NIH, SWOG, Isofol, Pfizer, BMS, G1 Therapeutics, Cardiff, Amal-KISIMA, Mirati, Merck, Bayer, Idera, UCB, PsOxius, NGM, OBI Pharma